JPAC Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee

Stem Cell Therapy

  • Fisher SA, Lamikanra A, Doree C, Gration B, Tsang P, Danby RD, Roberts DJ. 
    Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review. 
    British Journal of Haematology 2017; 176(3):448-463.
    Access abstract: PubMed / full text: Wiley (subscription may be required)
     

  • Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. 
    Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. 
    Cochrane Database Systematic Reviews 2016; (12):CD007888.
    Access abstract: PubMed / full text: Wiley (subscription may be required)
     

  • Fisher SA, Doree C, Taggart DP, Mathur A, Martin-Rendon E.
    Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews.
    Clinical Pharmacology and Therapeutics 2016; 100(1):88-101. doi: 10.1002/cpt.344.
    Access abstract: PubMed / full text: Wiley (subscription may be required)

  • Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E.
    Stem cell treatment for acute myocardial infarction.
    Cochrane Database of Systematic Reviews 2015;(9):CD006536.
    Access abstract: PubMed / full text: Wiley (subcription may be required)

  • Fisher SA, Doree C, Mathur A, Martin-Rendon E.
    Meta-analysis of cell therapy trials for patients with heart failure.
    Circulation Research 2015; 116(8):1361-77.
    Access abstract: PubMed / full text: Circulation Research (subscription required)

  • Harvey E, Fisher SA, Doree C, Taggart DP, Martin-Rendon E.
    Current evidence of the efficacy of cell-based therapies in heart failure.
    Circulation Journal 2015;79(2):229-36.
    Access abstract: PubMed / full text: Japanese Circulation Society (freely available)

  • Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E.
    Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.
    Cochrane Database of Systematic Reviews 2014;(4): CD007888.
    Access abstract: PubMed / full text: Wiley (subcription may be required)
     
  • Fisher SA, Doree C, Brunskill SJ, Mathur A, Martin-Rendon E.
    Bone marrow stem cell treatment for ischemic heart disease patients with no option of revascularization: a systematic review and meta-analysis.
    PLoS One 2013; 8(6):e64669.
    Access abstract: PubMed / full text: PLoS One (freely available)
     
  • Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Clarke MJ, Watt SM, Martin-Rendon E.
    Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes.
    PLoS One 2012; 7(5):e37373.
    Access abstract: PubMed / full text: PLoS One (freely available)
     
  • Martin-Rendon E, Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Clarke M, Watt SM.
    Long-term effect of stem cell treatment in acute myocardial infarction: what is new from 2008?
    Cardiovascular Research 2012; 93(Suppl 1): S57. Abstract No. P290.
    Access abstract: Oxford Journals (freely available)
     
  • Brunskill S, Hyde CJ, Doree C, Watt SM, Martin-Rendon E.
    Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease.
    European Journal of Heart Failure 2009; 11(9): 887-96.
    Access abstract: PubMed / full text: Oxford Journals (freely available)
     
  • Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM.
    Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review.
    European Heart Journal 2008; 29(15):1807-18.
    Access abstract: PubMed / full text: Oxford Journals (freely available)